Dezentrale klinische Prüfungen als Erweiterung der Konzepte klinischer Prüfungen

Dezentralisierte Studien (DCT – Decentralized Clinical Trials) rücken immer weiter in den Fokus – vor allen Dingen während der aktuellen Pandemie. 

Um DCTs ging es auch in der letzten „BfArM im Dialog“ (Bundesamt für Arzneimittel und Medizinprodukte)-Veranstaltung.

Der folgende Artikel gibt einen Überblick über die Veranstaltung, in der die Vor- und Nachteile inklusive der Herausforderungen, DCTs betreffend, dargelegt werden:

»» ARTIKEL ALS PDF ANZEIGEN


This website is using cookies to provide a good browsing experience

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

This website is using cookies to provide a good browsing experience

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Saved!